One company leads in gene-editing approvals, while the other targets surging demand in metabolic treatments. Here’s how their ...

Editorial: Polling shows that the public supports this new technology, but the conversation must move beyond simple questions of safety ...

Casgevy sickle cell gene therapy is now FDA-approved for children as young as two, opening access for 5,500 more U.S. kids.

The Europe transgenic animal model market is set for robust growth, driven by surging biotechnology investments, demand for ...

Casgevy also now indicated for transfusion-dependent beta thalassemia in children 2 years ...

CRISPR Therapeutics wins FDA pediatric approval for Casgevy, boosting market potential and pipeline upside despite slow uptake. Click here to read more.

For the first time, children in the US as young as two with the blood disorders sickle cell disease and beta thalassaemia are ...

Scribe Therapeutics is the latest biotech to prepare a public listing, as the company looks to propel its lipid-lowering medicines through clinical trials. While the Bay Area biotech has yet to set ...

Gene editing has delivered remarkable results against sickle cell disease. Now researchers are working to make these ...

Developing novel ways to refine, reduce and replace the use of animals in research and enhance animal and human health.

An extremely precise genome editing technique called base editing has been used for the first time by Cambridge scientists to ...

Hiroshima University researchers have demonstrated a proof of concept for the mass production of genome-edited T cells that ...